Mostrar el registro sencillo del ítem

dc.contributor.authorCaetano Cordeiro, Ana Sara
dc.contributor.authorAlonso Fernández, María José
dc.contributor.authorDe La Fuente Freire, María 
dc.date.accessioned2017-06-07T07:14:20Z
dc.date.available2017-06-07T07:14:20Z
dc.date.issued2015
dc.identifier.issn0734-9750
dc.identifier.urihttp://hdl.handle.net/20.500.11940/4177
dc.description.abstractCurrently, there are over 70 licensed vaccines, which prevent the pathogenesis of around 30 viruses and bacteria. Nevertheless, there are still important challenges in this area, which include the development of more active, non-invasive, and thermo-resistant vaccines. Important biotechnological advances have led to safer subunit antigens, such as proteins, peptides, and nucleic acids. However, their limited immunogenicity has demanded potent adjuvants that can strengthen the immune response. Particulate nanocarriers hold a high potential as adjuvants in vaccination. Due to their pathogen-like size and structure, they can enhance immune responses by mimicking the natural infection process. Additionally, they can be tailored for non-invasive mucosal administration (needle-free vaccination), and control the delivery of the associated antigens to a specific location and for prolonged times, opening room for single-dose vaccination. Moreover, they allow co-association of immunostimulatory molecules to improve the overall adjuvant capacity. The natural and ubiquitous character of polysaccharides, together with their intrinsic immunomodulating properties, their biocompatibility, and biodegradability, justify their interest in the engineering of nanovaccines. In this review, we aim to provide a state-of-the-art overview regarding the application of nanotechnology in vaccine delivery, with a focus on the most recent advances in the development and application of polysaccharide-based antigen nanocarriers.
dc.language.isoeng
dc.subject.meshAdjuvants, Immunologic
dc.subject.meshAntigens
dc.subject.meshChitosan
dc.subject.meshDextrans
dc.subject.meshHumans
dc.subject.meshMannans
dc.subject.meshNanotechnology
dc.subject.meshPolysaccharides
dc.subject.meshRecombinant Proteins
dc.subject.meshVaccines
dc.subject.meshVaccines, DNA
dc.subject.meshbeta-Glucans
dc.subject.meshAdjuvants
dc.subject.meshAntigen delivery
dc.subject.meshAntigens
dc.subject.meshNanovaccine
dc.subject.meshNeedle-free vaccination
dc.subject.meshPolysaccharides
dc.titleNanoengineering of vaccines using natural polysaccharides
dc.typeArtigoes
dc.authorsophosCordeiro, A. S.
dc.authorsophosAlonso, M. J.
dc.authorsophosde la Fuente, M.
dc.identifier.doi10.1016/j.biotechadv.2015.05.010
dc.identifier.isi362859100002
dc.identifier.pmid26049133
dc.identifier.sophos18597
dc.issue.number6 Pt 3
dc.journal.titleBIOTECHNOLOGY ADVANCES
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Oncoloxía médica
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initial1279
dc.page.final93
dc.rights.accessRightsopenAccess
dc.subject.decsAdyuvantes Inmunológicos
dc.subject.decsAntígenos
dc.subject.decsDextranos
dc.subject.decsMananos
dc.subject.decsNanotecnología
dc.subject.decsPolisacáridos
dc.subject.decsHumanos
dc.subject.decsProteínas Recombinantes
dc.subject.decsQuitosano
dc.subject.decsVacunación
dc.subject.decsVacunas
dc.subject.decsVacunas de ADN
dc.subject.decsbeta-Glucanos
dc.typesophosArtículo de Revisión
dc.volume.number33


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem